Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14688405rdf:typepubmed:Citationlld:pubmed
pubmed-article:14688405lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:14688405lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:14688405pubmed:issue1lld:pubmed
pubmed-article:14688405pubmed:dateCreated2004-1-7lld:pubmed
pubmed-article:14688405pubmed:abstractTextProduction of monoclonal antibodies requires immortalization of splenocytes by somatic fusion to a myeloma cell line partner (hybridomas). Although hybridomas can be immortal, they may depend on a feeder cell layer and may be genetically unstable. Since the inception of hybridoma technology, efforts to improve efficiency and stability of monoclonal antibody-producing cell lines have not brought about substantial progress. Moreover, suitable human multiple myeloma-derived cell lines for the production of human antibodies have been very difficult to develop. Here we report a strategy that greatly simplifies the generation of antibodies and eliminates the need for hybridomas. We show that splenocytes derived from transgenic mice harboring a mutant temperature-sensitive simian virus 40 large tumor antigen under the control of a mouse major histocompatibility promoter are conditionally immortal at permissive temperatures and produce monoclonal antibodies. This simple approach may become a method of choice for generation and production of both polyclonal and monoclonal antibodies with advantages in high-throughput discovery and antibody-based immunotherapy.lld:pubmed
pubmed-article:14688405pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:languageenglld:pubmed
pubmed-article:14688405pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:citationSubsetIMlld:pubmed
pubmed-article:14688405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14688405pubmed:statusMEDLINElld:pubmed
pubmed-article:14688405pubmed:monthJanlld:pubmed
pubmed-article:14688405pubmed:issn0027-8424lld:pubmed
pubmed-article:14688405pubmed:authorpubmed-author:ArapWadihWlld:pubmed
pubmed-article:14688405pubmed:authorpubmed-author:PasqualiniRen...lld:pubmed
pubmed-article:14688405pubmed:issnTypePrintlld:pubmed
pubmed-article:14688405pubmed:day6lld:pubmed
pubmed-article:14688405pubmed:volume101lld:pubmed
pubmed-article:14688405pubmed:ownerNLMlld:pubmed
pubmed-article:14688405pubmed:authorsCompleteYlld:pubmed
pubmed-article:14688405pubmed:pagination257-9lld:pubmed
pubmed-article:14688405pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:meshHeadingpubmed-meshheading:14688405...lld:pubmed
pubmed-article:14688405pubmed:year2004lld:pubmed
pubmed-article:14688405pubmed:articleTitleHybridoma-free generation of monoclonal antibodies.lld:pubmed
pubmed-article:14688405pubmed:affiliationUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. rpasqual@mdanderson.orglld:pubmed
pubmed-article:14688405pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14688405pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14688405pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14688405lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14688405lld:pubmed